OncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP), a biopharmaceutical company making strides in the $7.1 billion prostate cancer treatment space, has continued to show very strong action on the charts so far in 2017, up more than 100% in a little over five weeks of action. We have been closely watching the company this year, and can offer […]
Nymox Pharmaceutical Corporation (NASDAQ:NYMX)
OncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP) Provides Positive Update on ProscaVax Data
OncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP) has been one of our favorite new players in the $7.1 billion prostate cancer treatment market. The company just put out a new press release summarizing data that makes a strong case in the preparation of a coming Phase II trial of ProscaVax, which is OncBioMune’s lead pipeline asset. As noted […]
OncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP) Presents Interesting Picture as a Bite-Size Buyout Candidate
OncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP) is in an interesting phase of its existence. The company just solidified its sense of credibility in the space with a recent announcement of a productive meeting with top staffing scientists at the host hospital of the Company’s upcoming Phase 2 trial of ProscaVax for prostate cancer. That represents the first […]
